MedTrace Logo

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

NCT06414915 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-05-16

No results posted yet for this study

Summary

Currently, there are no standard treatment and relevant exploration for NSCLC patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with tislelizumab in the treatment of NSCLC with NED, in order to provide a new treatment option for NSCLC patients with NED.

Conditions

Interventions

DRUG

Surufatinib

250 mg, po, qd, q3w

DRUG

Tislelizumab

200mg, iv, q3w

Sponsors & Collaborators

  • National Cancer Center, China

    lead OTHER

Principal Investigators

  • Puyuan Xing, Doctorate · Department of Medical Oncology, National Cancer Center, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-06-01
Completion
2027-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06414915 on ClinicalTrials.gov